Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases

NCT ID: NCT07199413

Last Updated: 2025-09-30

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-03-01
• Study Completion Date: 2029-04-01

Brief Summary

This is a prospective, single-center, phase 1 basket trial that will evaluate the safety and feasibility of administering SV-BR-1-GM in combination with pembrolizumab to solid tumor oncology patients over nine cycles.

Detailed Description

This prospective, single-site, open-label, single-arm, phase 1 basket trial is designed to evaluate whether a SV-BR-1-GM vaccine and pembrolizumab combination therapy is safe and can be feasibly administered to solid cancer patients with brain metastases who progress on SOC therapy. Secondary objectives will determine the preliminary efficacy of the study regimen, while exploratory measurements will evaluate underlying mechanisms and biomarkers of response using patient biospecimens (peripheral blood and, when available, CSF). A total of 20 solid tumor oncology patients, accrued over a 24-month time period, will be treated with the SV-BR-1-GM vaccine and pembrolizumab over nine three-week cycles.

Conditions

Brain Metastases; Leptomeningeal Metastasis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Vaccine and Study Drugs

Group Type: EXPERIMENTAL

SV-BR-1-GM Vaccine

Intervention Type: BIOLOGICAL

\~20 X 10\^6 cells across 4 injection sites

Cyclophosphamide

Intervention Type: DRUG

300 mg/m\^2 Intravenous

Pembrolizumab

Intervention Type: DRUG

200 mg/m\^2 Intravenous

Interferon

Intervention Type: DRUG

0.18 mcg subcutaneous

Interventions

SV-BR-1-GM Vaccine

\~20 X 10\^6 cells across 4 injection sites

Intervention Type: BIOLOGICAL

Cyclophosphamide

300 mg/m\^2 Intravenous

Intervention Type: DRUG

Pembrolizumab

200 mg/m\^2 Intravenous

Intervention Type: DRUG

Interferon

0.18 mcg subcutaneous

Intervention Type: DRUG

Other Intervention Names

Cytoxan; Keytruda; Sylatron

Eligibility Criteria

Inclusion Criteria

1. Age ≥ 18 years.

2. Subject has a prior diagnosis of central nervous system (CNS) metastases per institutional standard of care and/or Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria on imaging.

3. Subject has disease progression of CNS metastases (brain and/or leptomeningeal metastases (LMD) ) with progression on ≥ 1 line of standard of care therapy.

4. Patients should have at least one metastasis approved by the research team that meets the following size requirements:

o Diagnosis and treatment response to measurable CNS and LMD will be per institutional and/or RANO-BM criteria modified to include the cut off point of 0.5 cm or higher.

1. Patients with recurrent and or progressive symptomatic or asymptomatic brain lesions and >0.5 cm and twice the magnetic resonance imaging (MRI) slice thickness are allowed.

2. Any recurrent or progressive brain lesions > 3 cm in size and or causing symptoms must be evaluated by the study team for SRC and or whole brain radiation therapy (WBRT) prior to study entry.

3. Patients with recurrent brain lesions that are not treatable with local therapy or WBRT are eligible.

4. An interval of at least 4 weeks after the end of whole brain radiation or for any surgical resection of brain lesions is permitted; an interval of at least 4 weeks or 5 half-lives (whichever is sorter) after the last cytotoxic, targeted, immunotherapeutic or investigational agent is permitted (prior to the start of DC vaccine).

5. Patients should have recovered from the AEs of prior therapy to baseline or Grade ≤ 1.

6. Patients with recurrent or progressive LMD are eligible.

5. Prior surgical resection of the brain metastases is allowed; patients must recover for at least four weeks prior to study enrollment.

6. Patients with extracranial disease are eligible as long as no signs of visceral crisis.

7. Prior immunotherapy is allowed.

8. No need for steroids for at least two weeks.

1. Patients who recently started steroids should have completed tapering to be eligible.

2. Patients who have been on chronic steroids are eligible as long as they are maintained on a dose of ≤ 10 mg of prednisone or equivalent.

9. Tumor not impinging on the middle cerebral artery/speech-motor strip.

10. Patients who undergo any other surgical procedures (other than SRS) must have recovered for at least 3-4 weeks before study entry.

11. Subject has a life expectancy of ≥ 12 weeks.

12. ECOG 0-2.

13. Preserved organ function.

1. ANC ≥ 1,000/µl

2. Platelets ≥ 10,000 µl

3. Hemoglobin ≥ 8 gm/dL

4. Bilirubin ≤ 1.5 mg/dL; those with Gilbert syndrome may be included if their total bilirubin is ≤ 3.0 × ULN and direct bilirubin ≤ 1.5 × ULN.

5. Creatinine clearance ≥ 50 mL/min

6. AST, ALT ≤ 2.5 times institutional upper limit

7. ALP ≤ 2.5 × institutional upper limit, with the exception that ALP of < 5 x ULN is acceptable in patients with elevated ALP due to bone metastases (in the absence of liver metastases).

14. Patients with lymphopenia are eligible at the discretion of the treating provider.

15. Female subjects must meet one of the following:

1. Postmenopausal for at least one year before enrollment, or surgically sterile (i.e., undergone bilateral oophorectomy).

2. Premenopausal is defined as someone who has had menses at any time in the preceding 12 months. Premenopausal women who are eligible for this trial will require a GnRH analogue and treating physician, per institutional guidelines, may choose to monitor the ovarian function with laboratory tests (FSH/LH/Estradiol) to ensure a complete menopausal status with cessation of menses.

i. Note: Pregnancy test should be administered per institutional guidelines.

16. Male patients must be willing to abstain from heterosexual activity and/or use a condom during treatment and three months after treatment discontinuation.

17. Willing to provide blood for biomarker assessments.

18. Optional CSF, when appropriate, for biomarker assessments (at the discretion of treating physician).

19. Ability to understand a written informed consent document, and the willingness to sign it.

18. Men who are sexually active and not willing to use effective contraceptives (e.g., condoms) during and 3 months after treatment.

19. Women who are pregnant or nursing.

20. Severe mental illness per physician's assessment.

Exclusion Criteria

1. History of allergic reactions or intolerance to immunotherapy.

2. History of active or untreated infection, such as chronic untreated infections, HIV, Hepatitis B, Hepatitis C, or tuberculosis.

3. History of active inflammatory or autoimmune disease (granulomatosis, polyangiitis, Graves' disease, rheumatoid arthritis, polyphisitis, uveitis, etc.), except for the following.

1. Vitiligo; alopecia

2. Hypothyroidism: stable on replacement therapy

3. Chronic skin disease that doesn't require steroid therapy.

4. Active celiac disease or inflammatory bowel disease

4. Presence of severe neurological symptoms and unable to participate in the study due to acute decompensation.

5. History of severe brain injury.

6. History of last dose of antineoplastic therapy ≤ 7 days prior to the first dose of study drug. If sufficient wash-out time has not occurred (defined as 5 half-lives of the prior antineoplastic therapy), a longer wash-out may be needed, as suggested by the study team.

7. Patients with myelodysplastic syndrome (MDS), leukemia, or active blood disorders.

8. Patients with prior history of poorly controlled diabetes, lung disease, primary immunodeficiency syndromes.

9. Severe cardiac disease as determined by the treating providers.

10. Life expectancy <12 weeks.

11. Acute spinal cord compression, unless considered to have received definitive treatment for this and clinical evidence of stable disease for at least 28 days.

12. Active treatment with prednisone >10 mg or equivalent steroid (e.g., >1.5 mg dexamethasone) per day and/or other immunosuppressive therapies (e.g., interferon, azathioprine, mycophenolate).

13. Presence of secondary malignancies (chronic lymphocytic leukemia [CLL], and other hematological or solid tumor malignancies), with the exception of in situ disease (ductal carcinoma in situ [DCIS], lobular carcinoma in situ [LCIS], cervical intraepithelial neoplasia [CIN], squamous cell and basal cell cancer, or remote history of successfully treated melanoma).

14. Active participation in other clinical trials evaluating an active investigational drug within the past four weeks.

15. Unresolved toxicities of NCI CTCAE Grade ≥ 2 such as neurotoxicity, cardiotoxicity, myelotoxicity, gastrointestinal, or others.

16. Patients who received prior immune checkpoint inhibitors (CPIs) and have not recovered from Grade ≥ 2 AEs related to CPIs.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medical College of Wisconsin

OTHER

Sponsor Role: lead

Responsible Party

Sailaja Kamaraju

Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Central Contacts

Medical College of Wisconsin Cancer Center Clinical Trials Office

Role: CONTACT

cccto@mcw.edu

866-680-0505 ext. 8900

Other Identifiers

IIT-KAMARAJU-ASTRO

Identifier Type: -

Identifier Source: org_study_id